ClinicalTrials.gg
Status unknownNCT03221088Updated Jul 19, 2017

A Study of PEG-somatropin in the Treatment of Children With Idiopathic Short Stature

A Phase 2 interventional study of Jintrolong® low dose group and Jintrolong® high dose group in Dwarfism, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Status unknown at 7 sites in China. Open to participants aged 4 Years to 9 Years. Per ClinicalTrials.gov, last updated 2017-07-19.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2017), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Jun 2015, registered Jul 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
4 Years to 9 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing Human Growth Hormone in Dwarfism — none open to participants now, 1 under way, none of them phase 3. Human Growth Hormone · Dwarfism.

Planned enrollment
Largest of 15
360 · median 68
Started
2015
the only one that year
Phase 2
3 of 15
none open now
Registered
12th of 15
by date
Lead sponsor
3 of 15
Changchun GeneScience Pharmaceutical Co., Ltd.

Among the 15 studies testing Human Growth Hormone in Dwarfism, this one has the largest planned enrollment, is the only one that started in 2015, is one of 3 in phase 2, and was the 12th registered.

Dwarfism

99 studies on the registry are indexed under Dwarfism; 12 are open to participants now.

Browse Dwarfism studies →

Open to participants now

None of the 15 studies testing Human Growth Hormone in Dwarfism is open now. The open studies under Dwarfism, anywhere →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 7 Dwarfism studies recruiting now, 1 sets no upper age limit and 5 stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 4 Years to 9 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing Human Growth Hormone in Dwarfism as a file.
02

Study summary

This study aims to explore the optimal dose of pegylated recombinant human growth hormone (PEG-rhGH) injection to treat children with idiopathic short stature (ISS), evaluate its safety and efficacy, and provide scientific and reliable evidence for the medication dosage in Phase III clinical study.

03

Conditions studied

  • Dwarfism

Browse trials for

04

Who can participate

Ages eligible
4 Years to 9 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Boys are between 4 and 9 years of age and girls are between 4 and 8 years of age.
  • Height \<-2 SD for chronological age.
  • Growth velocity\<5.0 cm/yr.
  • GH peak concentration ≥10.0 ng/mL in two different stimulation tests.
  • The difference of bone age (BA) and chronological age (CA) is within -2 to +2.
  • IGF-1 concentration is between -2 SDS to +2 SDS.
  • Prepubertal Status(Tanner Stage I).
  • Birth weight within the normal range.
  • Growth hormone treatment-naive.
  • Subjects are willing and able to cooperate to complete scheduled visits, treatment plans and laboratory tests and other procedures, to sign .

Exclusion criteria

Exclusion Criteria:

  • Subjects with abnormal liver and kidney functions ( > value; Cr > upper limit of normal value).
  • Subjects are positive for , HbsAg or HbeAg in Hepatitis B virus tests.
  • Subjects with known highly allergic constitution or allergy to product or its .
  • Subjects with systemic chronic disease and immune deficiency.
  • Patients diagnosed with tumor.
  • Patients with mental disease.
  • Patients with other types of abnormal growth and development.

    1. Growth hormone deficiency (GHD) (confirmed by GH stimulation test);
    2. Turner syndrome (confirmed by karyotype test of girls);
    3. Noonan syndrome (hypertelorism, pectus carinatum, hypophrenia, frequently with skin disease and congenital heart disease, missense mutation of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene on chromosome 12 for half of the patients, for both male and female patients);
    4. Laron sydrome (confirmed by IGF-1 generation test);
    5. Small for gestational age ( the birth height or weight is below the tenth percentile or 2 SD, with catch-up growth uncompleted at 2 years old).
  • Growth disorders caused by malnutrition or hypothyroidism (thyroid function test).
  • Congenital skeletal abnormalities or scoliosis, claudication.
  • Subjects with impaired glucose regulation (IGR) (including impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) ) or diabetes).
  • Subjects with abnormal electrolyte, blood gas analysis (vein), creatine kinase.
  • Subjects who took part in other clinical trials within 3 months.
  • Subjects who received medications which may interfere GH secretion or GH function, or other hormones within 3 months (such as sex , glucocorticoids, etc.).
  • For patients with potential high tumor risks such as tumor markers exceed normal range and some other relative information, they may be excluded from the treatment.
  • Other conditions which is inappropriate for this study in the opinion of the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    Jintrolong® low dose group

    PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.1 mg/kg/w by subcutaneous injection for 52 weeks.

    Drug: Jintrolong® low dose group · Drug: Jintrolong® high dose group

  • Experimental
    Jintrolong® high dose group

    PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.2 mg/kg/w by subcutaneous injection for 52 weeks.

    Drug: Jintrolong® low dose group · Drug: Jintrolong® high dose group

  • No intervention
    Negative control group

    Untreated Control Group

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Height Standard Deviation Score for Chronological Age (ΔHtSDSCA)

    Change in Height Standard Deviation Score for Chronological Age (ΔHtSDSCA) from Baseline to 52 weeks;ΔHtSDSCA=(height Yx - reference mean for CA Yx) / reference SD for CA Yx (Yx refers to the height value at particular timepoint x)

    Time frame: Baseline,52 weeks

Secondary outcomes

  1. Change in Annualized Height Velocity

    Annualized Height Velocity=12×(Height Yx - Height at Baseline)/(Date of Yx - Date of Baseline) (Yx refers to the height value at particular timepoint x)

    Time frame: Baseline,52 weeks

  2. Change in Bone Maturation

    Bone Maturation=(BA Yx-BA at Baseline)/(Date of Yx - Date of Baseline) (Yx refers to the BA value at particular timepoint x)

    Time frame: Baseline,52 weeks

  3. Change in IGF-1 Standard Deviation Score (IGF-1 SDS)

    GF-1 SDS=(IGF-1 Yx - reference mean for CA Yx) / reference SD for CA Yx (Yx refers to the IGF-1 value at particular timepoint x)

    Time frame: Baseline,52 weeks

  4. IGF-1/IGFBP-3 molar ratio at 52 weeks

    IGF-1/IGFBP-3 molar ration=\[IGF-1(ng/ml)/7.6\]/\[IGFBP-3 (ng/ml)/25.75\]

    Time frame: Baseline,52 weeks

07

Study locations

7 of 7 sites recruiting
  • Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Recruiting
    • Xiaoping Luo, PhD · Contact
  • The First Affiated Hospital of Nanjing Medical University
    Nanjing, Jiangsu, China
    Recruiting
    • Yuhua Hu, MD · Contact
  • Affiliated Hospital of Jiangnan University
    Wuxi, Jiangsu, China
    Recruiting
    • Zhuangjian Xu, MD · Contact
  • The First Hospital of Jilin University
    Changchun, Jilin, China
    Recruiting
    • Hongwei Du, MD · Contact
  • The Children's Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Recruiting
    • Junfen Fu, MD · Contact
  • Shanghai Children's Hospital of Fudan University
    Shanghai, China
    Recruiting
    • Feihong Luo, MD · Contact
  • Shanghai Children's Hospital
    Shanghai, China
    Recruiting
    • Pin Li, MD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2015 (actual). Primary completion is estimated for Dec 2018, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2017
First posted
Jul 18, 2017
StartActual
Jun 2015
Primary completionEst.
Dec 2018
Last update
Jul 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03221088
Collaborators
Tongji Hospital, The First Hospital of Jilin University, Affiliated Hospital of Jiangnan University, The First Affiliated Hospital with Nanjing Medical University, Shanghai Children's Hospital, The Children's Hospital of Zhejiang University School of Medicine, Children's Hospital of Fudan University
Responsible party
Sponsor
First posted
Jul 18, 2017
Start date
Jun 2015
Primary completion
Dec 2018 (estimated)
Last update
Jul 19, 2017

Study contacts

Yanlin Chen
Contact
chenyanlin@gensci-china.com
+86-60871786-8197
Xiaoping Luo
principal investigator · Department of Pediatrics of Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion